Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, multicenter, open-label study of DS-8201a in subjects with HER2-expressing advanced colorectal cancer

Trial Profile

A Phase 2, multicenter, open-label study of DS-8201a in subjects with HER2-expressing advanced colorectal cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab-deruxtecan (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Daiichi Sankyo Company; Daiichi Sankyo Inc
  • Most Recent Events

    • 08 Nov 2018 According to a Daiichi Sankyo Company media release, data from this trial was presented at the 2018 European Society for Medical Oncology (ESMO) Congress.
    • 31 Aug 2018 Biomarkers information updated
    • 07 Mar 2018 According to a Daiichi Sankyo Company media release, the first part of the study is expected to enroll approximately 50 patients, following the outcome of the first part of the study two additional exploratory cohorts may proceed to enroll patients whose tumors have lower levels of HER2-expression.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top